{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:28:04Z","timestamp":1795120084740,"version":"4.10.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antitumor necrosis factor (anti-TNF) biologics have revolutionized the treatment of inflammatory bowel disease (IBD). Previously, studies have shown an association between the HLADQA1*05 allele and the development of antibodies and were predictive of loss of response. We sought to investigate the rate of the HLADQA1*05 allele in patients with IBD at a New England center and its association with antibody development and discontinuation of anti-TNF therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A single center retrospective cohort study with patients on anti-TNF inhibitor therapy being followed at our IBD clinic who had testing performed for the HLADQA1*05 allele were identified and separated into 2 different groups: HLADQA1*05 positive (HLA carriers) or HLADQA1*05 negative (HLA noncarriers). Persistence of remaining on anti-TNF therapy, measurement of drug\/antibody levels, and need for dose escalation were collected and stratified amongst the 2 groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The prevalence of the HLADQA1*05 allele among all IBD patients followed was 53%. We identified 67 IBD patients being treated with anti-TNF medications, 46 (69%) patients with Crohn\u2019s disease and 21 (31%) with ulcerative colitis. Most of the HLA carriers (85%) and HLA noncarriers (92%) remained on anti-TNF therapy at the end of the study period. Thirty-six (84%) patients had therapeutic drug monitoring performed during maintenance therapy. Three patients in the HLA carrier group had meaningful antidrug antibody levels necessitating cessation of therapy compared to one patient in the HLA noncarrier group (P\u2005=\u2005.61). Only 3 (13%) of HLA carriers and 4 (21%) of HLA noncarriers were on combination therapy with an immunomodulator. 65% of HLA carriers required dose escalation compared to 50% of HLA noncarriers (P\u2005=\u2005.70).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The prevalence of the HLADQA1*05 allele was 53% in our New England IBD patient population, similar to what has previously been reported in European studies. The majority of patients remained on anti-TNF therapy at the end of the study period despite carrier status. While there was a trend toward increased need for dose escalation among HLA carriers, this was not statistically significant. Future studies are needed to determine if the presence of the HLADQA1*05 allele leads to antibody development against anti-TNF inhibitors and treatment failure in patients with IBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otae058","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T19:00:18Z","timestamp":1729710018000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-World Experience of the Association of HLADQA1*05 Allele With Loss of Response to Anti-TNF Inhibitors"],"prefix":"10.1093","volume":"6","author":[{"given":"Aastha","family":"Chokshi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Warren Alpert Medical School of Brown University , Providence, RI,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A","family":"Raker","sequence":"additional","affiliation":[{"name":"Department of Biostatistics\u00a0Lifespan, Epidemiology, Research Design, and Informatics Core , Providence, RI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-5773","authenticated-orcid":false,"given":"Sean","family":"Fine","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Warren Alpert Medical School of Brown University , Providence, RI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"9","key":"2024110907562988000_CIT0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024110907562988000_CIT0002","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"2024110907562988000_CIT0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology."},{"issue":"9317","key":"2024110907562988000_CIT0004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet (London, England)"},{"issue":"11","key":"2024110907562988000_CIT0005","doi-asserted-by":"crossref","first-page":"1756283X17750355","DOI":"10.1177\/1756283X17750355","article-title":"Immunogenicity of biologics in inflammatory bowel disease","author":"Vermeire","year":"2018","journal-title":"Ther Adv Gastroenterol."},{"issue":"15","key":"2024110907562988000_CIT0006","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med."},{"issue":"12","key":"2024110907562988000_CIT0007","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/gutjnl-2014-307126","article-title":"Systematic review: monotherapy with antitumour necrosis factor \u03b1 agents versus combination therapy with an immunosuppressive for IBD","volume":"63","author":"Dulai","year":"2014","journal-title":"Gut."},{"issue":"2","key":"2024110907562988000_CIT0008","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology."},{"issue":"1","key":"2024110907562988000_CIT0009","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology."},{"issue":"3","key":"2024110907562988000_CIT0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.15563","article-title":"HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease","volume":"51","author":"Wilson","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2024110907562988000_CIT0011","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ibd\/izac259","article-title":"Influence of HLADQA1*05 genotype in adults with inflammatory bowel disease and anti-TNF treatment with proactive therapeutic drug monitoring: a retrospective cohort study","volume":"29","author":"Fuentes-Valenzuela","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024110907562988000_CIT0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3349\/ymj.2007.48.1.11","article-title":"The HLA system: genetics, immunology, clinical testing, and clinical implications","volume":"48","author":"Choo","year":"2007","journal-title":"Yonsei Med J."},{"issue":"6","key":"2024110907562988000_CIT0013","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ibd\/izad130","article-title":"HLA-DQA1*05 was not associated with primary nonresponse or loss of response to first anti-TNF in real-world inflammatory bowel disease patients","volume":"30","author":"Pascual-Oliver","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2024110907562988000_CIT0014","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2022.01.009","article-title":"Failure to achieve target drug concentrations during induction and not HLA-DQA1*05 carriage is associated with antidrug antibody formation in patients with inflammatory bowel disease","volume":"162","author":"Spencer","year":"2022","journal-title":"Gastroenterology."},{"issue":"8","key":"2024110907562988000_CIT0015","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2024110907562988000_CIT0016","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology."},{"issue":"4","key":"2024110907562988000_CIT0017","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology."},{"issue":"8","key":"2024110907562988000_CIT0018","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024110907562988000_CIT0019","first-page":"12","article-title":"Mistakes in therapeutic drug monitoring of biologics in IBD and how to avoid them","volume":"23","author":"Papamichail","year":"2023","journal-title":"UEG Educ."},{"issue":"10","key":"2024110907562988000_CIT0020","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","article-title":"A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease","volume":"116","author":"Cheifetz","year":"2021","journal-title":"Am J Gastroenterol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae058\/60011224\/otae058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae058\/60555855\/otae058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae058\/60555855\/otae058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T07:56:57Z","timestamp":1731139017000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae058\/7833439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae058","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10,1]]},"article-number":"otae058"}}